Positions

Selected Publications

Academic Article

Year Title Altmetric
2018 Optimal Systolic Blood Pressure Target in Resistant and Non-Resistant Hypertension: A Pooled Analysis of Patient-Level Data from SPRINT and ACCORD.American Journal of Medicine.  131:1463-1472.e7. 2018
2018 Advances in resistant hypertension.Annals of translational medicine.  6:294. 2018
2018 Early feasibility of hypoglossal nerve upper airway stimulator in patients with cardiac implantable electronic devices and continuous positive airway pressure-intolerant severe obstructive sleep apnea.Heart Rhythm.  15:1165-1170. 2018
2018 Refractory Hypertension Is not Attributable to Intravascular Fluid Retention as Determined by Intracardiac Volumes.Hypertension.  72:343-349. 2018
2018 Cumulative Incidence of Hypertension by 55 Years of Age in Blacks and Whites: The CARDIA Study.Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease.  7. 2018
2018 Case of Refractory Hypertension Controlled After Aortic and Mitral Valve Replacement and Coronary Artery Bypass Grafting.Hypertension.  72:3-9. 2018
2018 Fluid retention, aldosterone excess, and treatment of resistant hypertension.Lancet Diabetes and Endocrinology.  6:431-433. 2018
2018 Medical Versus Surgical Treatment of Primary Aldosteronism.Hypertension.  71:566-568. 2018
2018 Role of Mineralocorticoid Receptors in Obstructive Sleep Apnea and Metabolic Syndrome.Current Hypertension Reports.  20:23. 2018
2018 The association of nocturnal hypertension and nondipping blood pressure with treatment-resistant hypertension: The Jackson Heart Study.Journal of Clinical Hypertension.  20:438-446. 2018
2018 Antihypertensive Medications and Falls in the Elderly.American Journal of Hypertension.  31:281-283. 2018
2018 The New ACC/AHA Hypertension Guidelines for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults.American Journal of Hypertension.  31:133-135. 2018
2017 Prevalence and Clinical Characteristics of Refractory Hypertension.Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease.  6. 2017
2017 True versus pseudoresistant hypertension.Journal of Hypertension.  35:2367-2368. 2017
2017 Glomerular Hyperfiltration in Obese African American Hypertensive Patients Is Associated With Elevated Urinary Mitochondrial-DNA Copy Number.American Journal of Hypertension.  30:1112-1119. 2017
2017 Refractory versus resistant hypertension: Novel distinctive phenotypes.Journal of nature and science.  3. 2017
2017 Treatment of primary aldosteronism is associated with a reduction in the severity of obstructive sleep apnoea.Journal of Human Hypertension.  31:561-567. 2017
2017 White-Coat Effect Is Uncommon in Patients With Refractory Hypertension.Hypertension.  70:645-651. 2017
2017 Sleep disorders and hypertension risk.Journal of Human Hypertension.  31:371-372. 2017
2017 Resistant Hypertension: An Update of Experimental and Clinical Findings.Hypertension.  70:5-9. 2017
2017 11-Beta Dehydrogenase Type 2 Activity Is Not Reduced in Treatment Resistant Hypertension.American Journal of Hypertension.  30:518-523. 2017
2017 Clinic and ambulatory blood pressure in a population-based sample of African Americans: the Jackson Heart Study.Journal of the American Society of Hypertension.  11:204-212.e5. 2017
2017 National patterns in intensity and frequency of outpatient care for apparent treatment-resistant hypertension.American Heart Journal.  186:29-39. 2017
2017 Treatment-Resistant Hypertension and Outcomes Based on Randomized Treatment Group in ALLHAT.American Journal of Medicine.  130:439-448.e9. 2017
2017 Distinctive Risk Factors and Phenotype of Younger Patients With Resistant Hypertension: Age Is Relevant.Hypertension.  69:827-835. 2017
2017 Use of Aldosterone Antagonists for Treatment of Uncontrolled Resistant Hypertension.American Journal of Hypertension.  30:103-109. 2017
2017 Association of 3 Different Antihypertensive Medications With Hip and Pelvic Fracture Risk in Older Adults: Secondary Analysis of a Randomized Clinical Trial.JAMA Internal Medicine.  177:67-76. 2017
2017 Effects of Spironolactone and Renal Denervation Treatment on Blood Pressure and Its Variability-Different Aspects of Hypertension Treatment.American Journal of Hypertension.  30:12-15. 2017
2017 Screening for endocrine hypertension: An endocrine society scientific statementRecent Progress in Hormone Research.  38:103-122. 2017
2017 Update From the Editors to Our Readers.American Journal of Hypertension.  30:1-2. 2017
2016 Sleep, insomnia, and hypertension: current findings and future directions.Journal of the American Society of Hypertension.  11:122-129. 2016
2016 Assessment of vascular function in low socioeconomic status preschool children: a pilot study.Journal of the American Society of Hypertension.  11:101-109. 2016
2016 Refractory versus resistant hypertension.Current Opinion in Nephrology and Hypertension.  26:14-19. 2016
2016 Sympathetic Activity, Hypertension, and The Importance of a Good Night's Sleep.Hypertension.  68:1338-1339. 2016
2016 BP Targets in Hypertension: What Should We Do Now That SPRINT Is Out?Current Cardiology Reports.  18:98. 2016
2016 OS 24-04 A PILOT STUDY ASSESSING THE FEASIBILITY OF VASCULAR FUNCTION IN LOW SOCIOECONOMIC STATUS PRESCHOOL CHILDREN.Journal of Hypertension.  34 Suppl 1:e244. 2016
2016 OS 33-02 IN PATIENTS WITH RESISTANT HYPERTENSION INCREASED 24-H URINARY CORTISOL LEVEL PREDICT INCREASED BODY MASS INDEX.Journal of Hypertension.  34 Suppl 1:e393. 2016
2016 OS 33-02 IN PATIENTS WITH RESISTANT HYPERTENSION INCREASED 24-H URINARY CORTISOL LEVEL PREDICT INCREASED BODY MASS INDEX.Journal of Hypertension.  34 Suppl 1 - ISH 2016 Abstract Book:e393. 2016
2016 Refractory and Resistant Hypertension: Antihypertensive Treatment Failure versus Treatment Resistance.Korean Circulation Journal.  46:593-600. 2016
2016 SY 14-3 PRIMARY ALDOSTERONISM IN RESISTANT HYPERTENSION.Journal of Hypertension.  34 Suppl 1:e369. 2016
2016 SY 14-3 PRIMARY ALDOSTERONISM IN RESISTANT HYPERTENSION.Journal of Hypertension.  34 Suppl 1 - ISH 2016 Abstract Book:e369. 2016
2016 Spironolactone versus renal nerve denervation for treatment of uncontrolled resistant hypertension.Journal of Hypertension.  34:1701-1703. 2016
2016 Renal Nerve Denervation, Adherence, and Management of Resistant Hypertension.Circulation.  134:858-860. 2016
2016 The effects of urate lowering therapy on inflammation, endothelial function, and blood pressure (SURPHER) study design and rationale.Controlled Clinical Trials.  50:238-244. 2016
2016 Body Mass Index Predicts 24-Hour Urinary Aldosterone Levels in Patients With Resistant Hypertension.Hypertension.  68:995-1003. 2016
2016 Comparisons of sleep apnoea rate and outcomes among patients with resistant and non-resistant hypertension.Respirology.  21:1486-1492. 2016
2016 Do We Need a New Definition of Hypertension After SPRINT?American Journal of Hypertension.  29:1127-1129. 2016
2016 A practical approach for measurement of antihypertensive medication adherence in patients with resistant hypertension.Journal of the American Society of Hypertension.  10:510-516.e1. 2016
2016 Prevalence of pseudoresistant hypertension due to inaccurate blood pressure measurement.Journal of the American Society of Hypertension.  10:493-499. 2016
2016 Refractory Hypertension: A Novel Phenotype of Antihypertensive Treatment Failure.Hypertension.  67:1085-1092. 2016
2016 Resistant and Refractory Hypertension: Antihypertensive Treatment Resistance vs Treatment Failure.Canadian Journal of Cardiology.  32:603-606. 2016
2016 Urinary sodium excretion predicts blood pressure response to spironolactone in patients with resistant hypertension independent of aldosterone status.Journal of Hypertension.  34:1005-1010. 2016
2016 Drug Development for Hypertension: Do We Need Another Antihypertensive Agent for Resistant Hypertension?Current Hypertension Reports.  18:25. 2016
2016 Introduction to the American Heart Association's Hypertension Strategically Focused Research Network.Hypertension.  67:674-680. 2016
2016 Effects of 6-month supplementation with β-hydroxy-β-methylbutyrate, glutamine and arginine on vascular endothelial function of older adults.European Journal of Clinical Nutrition.  70:269-273. 2016
2016 Endothelial Cell Bioenergetics and Mitochondrial DNA Damage Differ in Humans Having African or West Eurasian Maternal Ancestry.Circulation: Cardiovascular Genetics.  9:26-36. 2016
2016 Obesity, African American Race, Chronic Kidney Disease, and Resistant Hypertension: The Step Beyond Observed Risk.Hypertension.  67:275-277. 2016
2016 A Message From the New Editorial Team at the American Journal of Hypertension.American Journal of Hypertension.  29:1. 2016
2016 SPRINT Proves that Lower Is Better for Nondiabetic High-Risk Patients, but at a Price.American Journal of Hypertension.  29:2-4. 2016
2015 Obstructive sleep apnea, hypertension and cardiovascular diseases.Journal of Human Hypertension.  29:705-712. 2015
2015 Nocturnal Blood Pressure in Young Adults and Cognitive Function in Midlife: The Coronary Artery Risk Development in Young Adults (CARDIA) Study.American Journal of Hypertension.  28:1240-1247. 2015
2015 Comparative risk of renal, cardiovascular, and mortality outcomes in controlled, uncontrolled resistant, and nonresistant hypertension.Kidney International.  88:622-632. 2015
2015 Apparent Treatment-resistant Hypertension Among Individuals with History of Stroke or Transient Ischemic Attack.American Journal of Medicine.  128:707-14.e2. 2015
2015 Refractory Hypertension: Evidence of Heightened Sympathetic Activity as a Cause of Antihypertensive Treatment Failure.Hypertension.  66:126-133. 2015
2015 Editorial comment: change in leadership.Journal of Human Hypertension.  29:339. 2015
2015 Racial differences in abnormal ambulatory blood pressure monitoring measures: Results from the Coronary Artery Risk Development in Young Adults (CARDIA) study.American Journal of Hypertension.  28:640-648. 2015
2015 Effect of spironolactone on diastolic function in hypertensive left ventricular hypertrophy.Journal of Human Hypertension.  29:241-246. 2015
2015 Results of an Academic, Health Care Worksite Weight Loss Contest for Southeastern Americans: Scale Back Alabama 2011-2013.Workplace Health and Safety.  63:165-169. 2015
2015 Management of hypertension in CKD: beyond the guidelines.Advances in Renal Replacement Therapy.  22:116-122. 2015
2015 Regional Heterogeneity in 3D Myocardial Shortening in Hypertensive Left Ventricular Hypertrophy: A Cardiovascular CMR Tagging Substudy to the Life Study.Journal of Biomedical Science and Engineering.  8:213-225. 2015
2015 Predictors of silent myocardial ischemia in resistant hypertensive patients.American Journal of Hypertension.  28:200-207. 2015
2015 Apparent treatment-resistant hypertension among individuals with history of stroke or transient ischemic attackAmerican Journal of Medicine.  128:707-714.e2. 2015
2014 Stroke outcomes among participants randomized to chlorthalidone, amlodipine or lisinopril in ALLHAT.Journal of the American Society of Hypertension.  8:808-819. 2014
2014 Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).Hypertension.  64:1012-1021. 2014
2014 Detection, evaluation, and treatment of severe and resistant hypertension: proceedings from an American Society of Hypertension Interactive forum held in Bethesda, MD, U.S.A., October 10th 2013.Journal of the American Society of Hypertension.  8:743-757. 2014
2014 Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus.Hypertension.  64:731-737. 2014
2014 Left ventricular torsion shear angle volume analysis in patients with hypertension: a global approach for LV diastolic function.Journal of Cardiovascular Magnetic Resonance.  16:70. 2014
2014 Healthy lifestyle factors and risk of cardiovascular events and mortality in treatment-resistant hypertension: the Reasons for Geographic and Racial Differences in Stroke study.Hypertension.  64:465-471. 2014
2014 Apparent and true resistant hypertension: definition, prevalence and outcomes.Journal of Human Hypertension.  28:463-468. 2014
2014 Characterizing workers participating in a worksite wellness health screening program using blood pressure control, self-monitoring, medication adherence, depression, and exercise.Workplace Health and Safety.  62:292-300. 2014
2014 Heart rate and heart rate variability in resistant versus controlled hypertension and in true versus white-coat resistance.Journal of Human Hypertension.  28:416-420. 2014
2014 Apparent treatment-resistant hypertension and risk for stroke, coronary heart disease, and all-cause mortality.Journal of the American Society of Hypertension.  8:405-413. 2014
2014 Incident ESRD and treatment-resistant hypertension: the reasons for geographic and racial differences in stroke (REGARDS) study.American Journal of Kidney Diseases.  63:781-788. 2014
2014 Response to should more significance be granted to medication response to antihypertensives in patients with resistant hypertension?Hypertension.  63:e84. 2014
2014 Management of Resistant Hypertension: Do Not Give Up on Medication.Nephrology self-assessment program : NephSAP.  13:57-63. 2014
2014 Refractory hypertension: determination of prevalence, risk factors, and comorbidities in a large, population-based cohort.Hypertension.  63:451-458. 2014
2014 Response to Comment on optimal treatment for resistant hypertension: the missing data on pulse wave velocity.Hypertension.  63:e17-e18. 2014
2014 Associations between vascular health indices and serum total, free and bioavailable 25-hydroxyvitamin D in adolescents.PLoS ONE.  9:e114689. 2014
2014 Pathophysiology and treatment of resistant hypertension: the role of aldosterone and amiloride-sensitive sodium channels.Seminars in Nephrology.  34:532-539. 2014
2013 Management of patients with resistant hypertension: current treatment options.Integrated Blood Pressure Control.  6:139-151. 2013
2013 Characteristics of resistant hypertension in a large, ethnically diverse hypertension population of an integrated health system.Mayo Clinic Proceedings.  88:1099-1107. 2013
2013 Increased circulating inflammatory endothelial cells in blacks with essential hypertension.Hypertension.  62:585-591. 2013
2013 Prevalence of apparent treatment-resistant hypertension among individuals with CKD.Clinical Journal of the American Society of Nephrology.  8:1583-1590. 2013
2013 Effects of demographics on the antihypertensive efficacy of triple therapy with amlodipine, valsartan, and hydrochlorothiazide for moderate to severe hypertension.Current Medical Research and Opinion.  29:901-910. 2013
2013 Response.Chest.  144:720. 2013
2013 Increased dietary sodium is related to severity of obstructive sleep apnea in patients with resistant hypertension and hyperaldosteronism.Chest.  143:978-983. 2013
2013 The contributions of unhealthy lifestyle factors to apparent resistant hypertension: findings from the Reasons for Geographic And Racial Differences in Stroke (REGARDS) study.Journal of Hypertension.  31:370-376. 2013
2013 Aldosterone receptor antagonists: current perspectives and therapies.Vascular Health and Risk Management.  9:321-331. 2013
2013 Hyperaldosteronism as a common cause of resistant hypertension.Annual Review of Medicine.  64:233-247. 2013
2012 Prevalence and correlates of low medication adherence in apparent treatment-resistant hypertension.Journal of Clinical Hypertension.  14:694-700. 2012
2012 Editorial introducing David as EiCJournal of Human Hypertension.  26:517. 2012
2012 Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease.Journal of Human Hypertension.  26:502-506. 2012
2012 Serum 25-hydroxyvitamin D and Ethnic Differences in Arterial Stiffness and Endothelial Function.Journal of Clinical Medicine Research.  4:197-205. 2012
2012 Response to letter to regarding article, "Effects of novel aldosterone synthase inhibitor for treatment of primary hypertension: Results of a randomized, double-blind, placebo- and active-controlled phase 2 trial"Circulation.  125. 2012
2012 Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.Hypertension.  59:926-933. 2012
2012 Hypertensive crisis: forget the numbers.Journal of Hypertension.  30:882-883. 2012
2012 Resistant hypertension and aldosterone: an update.Canadian Journal of Cardiology.  28:318-325. 2012
2012 Resistant hypertension, obstructive sleep apnoea and aldosterone.Journal of Human Hypertension.  26:281-287. 2012
2012 Resistant hypertension: incidence, prevalence, and prognosis.Circulation.  125:1594-1596. 2012
2012 Relation of torsion and myocardial strains to LV ejection fraction in hypertension.JACC: Cardiovascular Imaging.  5:273-281. 2012
2012 Association of filtered sodium load with medullary volumes and medullary hypoxia in hypertensive African Americans as compared with whites.American Journal of Kidney Diseases.  59:229-237. 2012
2012 Associations of C-Reactive Protein to Indices of Vascular Health and the Influence of Serum 25(OH)D Status in Healthy Adults.Journal of Nutrition and Metabolism.  2012:475975. 2012
2012 Both morning and evening dosing of nebivolol reduces trough mean blood pressure surge in hypertensive patients.Journal of the American Society of Hypertension.  6:66-72. 2012
2012 Hypertension and orthostatic hypotension in older patients.Journal of Hypertension.  30:38-39. 2012
2012 Recent advancements in the treatment of resistant hypertension.Postgraduate Medicine.  124:67-73. 2012
2012 Refractory hypertension: definition, prevalence, and patient characteristics.Journal of Clinical Hypertension.  14:7-12. 2012
2011 Resistant HypertensionCurrent Cardiovascular Risk Reports.  5:307-313. 2011
2011 Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial.Circulation.  124:1945-1955. 2011
2011 Non-dipping pattern relates to endothelial dysfunction in patients with uncontrolled resistant hypertension.Journal of Human Hypertension.  25:656-664. 2011
2011 24-Hour ambulatory blood pressure control with triple-therapy amlodipine, valsartan and hydrochlorothiazide in patients with moderate to severe hypertension.Journal of Human Hypertension.  25:615-622. 2011
2011 Characteristics of resistant hypertension: ageing, body mass index, hyperaldosteronism, cardiac hypertrophy and vascular stiffness.Journal of Human Hypertension.  25:532-538. 2011
2011 Gene variation in resistant hypertension: multilocus analysis of the angiotensin 1-converting enzyme, angiotensinogen, and endothelial nitric oxide synthase genes.DNA (Mary Ann Liebert, Inc.).  30:555-564. 2011
2011 Positive relationship of sleep apnea to hyperaldosteronism in an ethnically diverse population.Journal of Hypertension.  29:1553-1559. 2011
2011 Resistant hypertension: bad and getting worse.Hypertension.  57:1045-1046. 2011
2011 Moderate waist circumference and hypertension prevalence: the REGARDS Study.American Journal of Hypertension.  24:482-488. 2011
2011 Aldosteronism and resistant hypertension.International Journal of Hypertension.  2011:837817. 2011
2011 Apparent resistant hypertension and medication adherence.Hypertension Research.  34:41-42. 2011
2011 Geographic and demographic variability in 20-year hypertension incidence: the CARDIA study.Hypertension.  57:39-47. 2011
2010 Resistant hypertension, secondary hypertension, and hypertensive crises: diagnostic evaluation and treatment.Cardiology Clinics.  28:639-654. 2010
2010 Salt and aldosterone: a concert of bad effects.Hypertension.  56:804-805. 2010
2010 Treatment of resistant hypertension.Journal of Hypertension.  28:2194-2195. 2010
2010 Response to hyperaldosteronism and left ventricular hypertrophyHypertension.  56. 2010
2010 Severity of obstructive sleep apnea is related to aldosterone status in subjects with resistant hypertension.Journal of Clinical Sleep Medicine.  6:363-368. 2010
2010 Sleep and hypertension.Chest.  138:434-443. 2010
2010 Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report.Journal of Human Hypertension.  24:532-537. 2010
2010 The role of aldosteronism in causing obesity-related cardiovascular risk.Cardiology Clinics.  28:517-527. 2010
2010 Effectiveness of initiating treatment with valsartan/hydrochlorothiazide in patients with stage-1 or stage-2 hypertension.Journal of Human Hypertension.  24:483-491. 2010
2010 Obstructive sleep apnea and hypertension.Current Hypertension Reports.  12:189-195. 2010
2010 Rapid reversal of left ventricular hypertrophy and intracardiac volume overload in patients with resistant hypertension and hyperaldosteronism: a prospective clinical study.Hypertension.  55:1137-1142. 2010
2010 Response to "effective" plasma renin activity: A derived measure for assessing residual plasma renin activity in patients taking angiotensin-converting enzyme inhibitors or angiotensin receptor blockersHypertension.  55. 2010
2009 Reduction of blood pressure in patients with treatment-resistant hypertension.Expert Opinion on Pharmacotherapy.  10:2959-2971. 2009
2009 Treatment of resistant hypertension.Minerva Cardioangliologica.  57:787-812. 2009
2009 Amlodipine/valsartan/hydrochlorothiazide triple combination therapy in moderate/severe hypertension: Secondary analyses evaluating efficacy and safety.Advances in Therapy.  26:1012-1023. 2009
2009 Characterization and treatment of resistant hypertension.Current Cardiology Reports.  11:407-413. 2009
2009 Current options for the treatment of resistant hypertension.Expert Review of Cardiovascular Therapy.  7:1385-1393. 2009
2009 Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial.Hypertension.  54:475-481. 2009
2009 A dual propagation contours technique for semi-automated assessment of systolic and diastolic cardiac function by CMR.Journal of Cardiovascular Magnetic Resonance.  11:30. 2009
2009 Use of single-pill combination therapy in the evolving paradigm of hypertension management.Expert Opinion on Pharmacotherapy.  10:1869-1874. 2009
2009 Efficacy and safety of initial combination therapy with amlodipine/valsartan compared with amlodipine monotherapy in black patients with stage 2 hypertension: the EX-STAND study.Journal of Human Hypertension.  23:479-489. 2009
2009 Resistant hypertension: who and how to evaluate.Current Opinion in Cardiology.  24:340-344. 2009
2009 Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial.Hypertension.  54:32-39. 2009
2009 Aldosterone and metabolic dysfunction: an unresolved issue.Hypertension.  53:585-586. 2009
2009 Sleep apnea, aldosterone, and resistant hypertension.Progress in Cardiovascular Diseases.  51:371-380. 2009
2008 Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension.Journal of the American Society of Hypertension.  2:462-468. 2008
2008 Efficacy and tolerability of combination therapy with valsartan/hydrochlorothiazide in the initial treatment of severe hypertension.Current Medical Research and Opinion.  24:2303-2311. 2008
2008 Marked regional left ventricular heterogeneity in hypertensive left ventricular hypertrophy patients: a losartan intervention for endpoint reduction in hypertension (LIFE) cardiovascular magnetic resonance and echocardiographic substudy.Hypertension.  52:279-286. 2008
2008 2008 American Heart Association Statement on diagnosis, evaluation, and treatment of resistant hypertension: what should we remember in everyday practice?Pol Arch Med Wewn.  118:396-397. 2008
2008 Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion.Archives of Internal Medicine -New Series-.  168:1159-1164. 2008
2008 Relation of dietary salt and aldosterone to urinary protein excretion in subjects with resistant hypertension.Hypertension.  51:339-344. 2008
2008 Response to about an epidemic of primary aldosteronism [2]Hypertension.  51. 2008
2007 High blood pressure in older adults: a conversation with Dr David Calhoun.American Journal of Geriatric Cardiology.  16:391-392. 2007
2007 Resistant hypertension and aldosteronism.Current Hypertension Reports.  9:353-359. 2007
2007 Aldosterone excess and resistance to 24-h blood pressure control.Journal of Hypertension.  25:2131-2137. 2007
2007 Is there an unrecognized epidemic of primary aldosteronism? Pro.Hypertension.  50:447-453. 2007
2007 Mechanisms and treatment of resistant hypertension.Arquivos Brasileiros de Cardiologia.  88:683-692. 2007
2007 Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension.Chest.  131:453-459. 2007
2007 Low-dose aldosterone blockade as a new treatment paradigm for controlling resistant hypertension.Journal of Clinical Hypertension.  9:19-24. 2007
2006 Aldosterone and cardiovascular disease: smoke and fire.Circulation.  114:2572-2574. 2006
2006 Primary aldosteronism: diagnosis and treatment.Journal of Clinical Hypertension.  8:887-893. 2006
2006 Aldosteronism and hypertension.Clinical Journal of the American Society of Nephrology.  1:1039-1045. 2006
2006 Aldosterone, dietary salt, and renal disease.Hypertension.  48:209-210. 2006
2006 Aldosterone antagonists: effective add-on therapy for the treatment of resistant hypertension.Expert Review of Cardiovascular Therapy.  4:353-359. 2006
2006 Use of aldosterone antagonists in resistant hypertension.Progress in Cardiovascular Diseases.  48:387-396. 2006
2006 Cardiovascular risk of systolic versus diastolic blood pressure in Western and non-Western countries.Journal of Hypertension.  24:435-436. 2006
2006 Resistant or difficult-to-treat hypertension.Journal of Clinical Hypertension.  8:181-186. 2006
2005 Primary aldosteronism: diagnostic and therapeutic considerations.Current Cardiology Reports.  7:412-417. 2005
2005 The role of aldosterone antagonists in the management of resistant hypertension.Current Hypertension Reports.  7:343-347. 2005
2005 Aldosterone antagonism: an emerging strategy for effective blood pressure lowering.Current Hypertension Reports.  7:186-192. 2005
2005 Validity of plasma aldosterone-to-renin activity ratio in African American and white subjects with resistant hypertension.American Journal of Hypertension.  18:805-812. 2005
2004 Weight gain and hypertension: the chicken-egg question revisited.Journal of Hypertension.  22:1869-1871. 2004
2004 Once-daily eprosartan mesylate in the treatment of elderly patients with isolated systolic hypertension: data from a 13-week double-blind, placebo-controlled, parallel, multicenter study.Journal of Human Hypertension.  18:655-661. 2004
2004 Use of aldosterone antagonists in resistant hypertension.Journal of Clinical Hypertension.  6:458-460. 2004
2004 Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism.Circulation.  109:2857-2861. 2004
2004 Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea.Chest.  125:112-117. 2004
2004 Attitudes about and psychosocial outcomes of HFE genotyping for hemochromatosis.Genetic Testing.  8:90-97. 2004
2003 Pathogenesis of hypertension.Annals of Internal Medicine.  139:761-776. 2003
2003 Efficacy of low-dose spironolactone in subjects with resistant hypertension.American Journal of Hypertension.  16:925-930. 2003
2003 Prevalence of renal artery stenosis in high-risk veterans referred to cardiac catheterizationJournal of Hypertension.  21:1157-1162. 2003
2003 Prevalence of renal artery stenosis in high-risk veterans referred to cardiac catheterization.Journal of Hypertension.  21:1157-1162. 2003
2003 Efficacy of Low-Dose Spironolactone in Subjects with Resistant HypertensionAmerican Journal of Hypertension.  16:925-930. 2003
2002 Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).Journal of the American Medical Association.  288:2981-2997. 2002
2002 Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).Journal of the American Medical Association.  288:2998-3007. 2002
2002 Hyperaldosteronism among black and white subjects with resistant hypertension.Hypertension.  40:892-896. 2002
2002 Drugs targeting the renin-angiotensin-aldosterone system.Nature Reviews Drug Discovery.  1:621-636. 2002
2002 Resistant hypertension.Current Hypertension Reports.  4:221-228. 2002
2001 Hyperactive ENaC identifies hypertensive individuais amenable to amiloride therapyAmerican Journal of Physiology - Cell Physiology.  281. 2001
2001 Enalaprilat blunts reflexive increases in cardiac interstitial norepinephrine in conscious rats.Journal of Hypertension.  19:2025-2029. 2001
2001 Hyperactive ENaC identifies hypertensive individuals amenable to amiloride therapy.American Journal of Physiology - Cell Physiology.  281:C1413-C1421. 2001
2001 Losartan versus valsartan in the treatment of patients with mild to moderate essential hypertension: data from a multicenter, randomized, double-blind, 12-week trial.Clinical Therapeutics.  23:1166-1179. 2001
2000 Evaluation of low-dose endotoxin administration during pregnancy as a model of preeclampsia.Anesthesiology.  93:1446-1455. 2000
1999 Contemporary management of refractory hypertension.Current Hypertension Reports.  1:402-407. 1999
1999 Interaction between lifetime captopril treatment and NaCI-sensitive hypertension in spontaneously hypertensive rats and Wistar-Kyoto rats.Journal of Hypertension.  17:983-991. 1999
1999 Pretreatment with enalaprilat blunts nicardipine-induced sympathetic activation in spontaneously hypertensive and Wistar-Kyoto rats.Journal of Hypertension.  17:507-512. 1999
1998 The Sexual Dimorphism of High Blood Pressure.Cardiology in Review.  6:356-363. 1998
1998 Managing the patient with hard-to-control hypertension.American Family Physician.  57:1007-1020. 1998
1997 Race, family history of hypertension, and sympathetic response to cold pressor testing.Blood Pressure.  6:209-213. 1997
1997 High blood pressure in women.International Journal of Fertility and Womens Medicine.  42:198-205. 1997
1997 Fenoldopam: A novel, peripherally acting dopamine-1 agonist for parenteral treatment of hypertensionDrugs of Today.  33:729-738. 1997
1996 Atrial natriuretic peptide blunts arterial baroreflex in spontaneously hypertensive rats.Hypertension.  27:297-302. 1996
1996 Hypertension: Initial evaluationACC Current Journal Review.  5:60-62. 1996
1996 Ovariectomy induces NaCl-sensitivity in female spontaneously hypertensive ratsJournal of Investigative Medicine.  44. 1996
1995 Racial differences in the pathogenesis of hypertension.American Journal of the Medical Sciences.  310 Suppl 1:S86-S90. 1995
1995 Calcium antagonists: Antihypertensive and vascular considerationsCardiovascular Reviews and Reports.  16. 1995
1995 Gender and dietary NaCl in spontaneously hypertensive and Wistar-Kyoto rats.Hypertension.  26:285-289. 1995
1995 Hypertensive crisis since FDR--a partial victory.New England Journal of Medicine.  332:1029-1030. 1995
1994 Muscle sympathetic nervous system activity in black and Caucasian hypertensive subjects.Journal of Hypertension.  12:1291-1296. 1994
1994 Diurnal blood pressure variation and dietary salt in spontaneously hypertensive rats.Hypertension.  24:1-7. 1994
1993 Normotensive blacks have heightened sympathetic response to cold pressor test.Hypertension.  22:801-805. 1993
1993 Excitatory sympathetic reflex in NaCl-sensitive spontaneously hypertensive rats.Hypertension.  22:285-291. 1993
1992 Hypertension in blacks: socioeconomic stress and sympathetic nervous system activity.American Journal of the Medical Sciences.  304:306-311. 1992
1992 Atrial natriuretic peptide modulates baroreceptor reflex in spontaneously hypertensive rat.Hypertension.  20:374-379. 1992
1991 The calcium antagonists in the 1990s. An overview.American Journal of Hypertension.  4:396S-405S. 1991
1991 Treatment of hypertensive crisis.New England Journal of Medicine.  324:992-994. 1991
1991 High NaCl diet enhances arterial baroreceptor reflex in NaCl-sensitive spontaneously hypertensive rats.Hypertension.  17:363-368. 1991
1991 The calcium antagonists in the 1990s an overviewAmerican Journal of Hypertension.  4:396S-405S. 1991
1990 Treatment of hypertensive crisis.New England Journal of Medicine.  323:1177-1183. 1990
1989 Hypertension.Disease-A-Month.  35:133-232. 1989
1989 HypertensionDisease-A-Month.  35:138-232. 1989

Chapter

Year Title Altmetric
2013 Resistant hypertension.  253-269. 2013
2013 Pathogenesis of Hypertension.  12-26. 2013
2012 Resistant hypertension.  501-509. 2012
2010 Hypertensive Emergencies.  355-367. 2010
2007 Pathophysiology of Hypertension.  25-46. 2007
2007 Resistant Hypertension.  658-665. 2007
2005 Resistant Hypertension.  616-623. 2005
2004 Hypertension and Sympathetic Nervous System Activity.  241-244. 2004

Research Overview

  • Resistant and difficult to treat hypertension Obstructive sleep apnea & hypertension
  • Principal Investigator On

  • Private Grant  awarded by IDORSIA PHARMACEUTICALS LTD 2018 - 2023
  • Private Grant  awarded by RECOR MEDICAL 2016 - 2023
  • University of Alabama at Birmingham Strategically Focused Hypertension Research Center - Mechanisms of Nocturnal Hypertension and Non-Dipping Blood Pressure - Project 2  awarded by American Heart Association 2015 - 2019
  • Mechanisms of Refractory Hypertension  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2014 - 2019
  • Private Grant  awarded by GEORGE CLINICAL 2017 - 2018
  • Private Grant  awarded by MEDTRONIC, INC. 2012 - 2018
  • Effect of Standard vs. Intense Clinic Based Hypertension Management on Nighttime Blood Pressure (SPRINT Ancillary Study)  awarded by University of Minnesota 2013 - 2016
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2014 - 2015
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2013 - 2014
  • Etiology of Sleep Apnea-Related Hyperaldosteronism  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2008 - 2014
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2011 - 2013
  • Private Grant  awarded by FOREST RESEARCH INSTITUTE, INC. 2012 - 2013
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2009 - 2012
  • Private Grant  awarded by ELI LILLY AND COMPANY 2010 - 2011
  • Irreversible Kidney Injury in Renovascular Hypertension  awarded by MAYO CLINIC 2010 - 2011
  • Establishment of 2 Research Beds with Full Sleep-Monitoring Capabilities  awarded by UNIVERSITY OF ALABAMA HEALTH SERVICES FOUNDATION 2006 - 2011
  • SCCOR in Cardiac Dysfunction and Disease - Project 2  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2005 - 2010
  • Investigator On

  • Private Grant  awarded by ROX MEDICAL INC. 2018 - 2023
  • Private Grant  awarded by INSPIRE MEDICAL SYSTEMS, INC. 2017 - 2023
  • Private Grant  awarded by VASCULAR DYNAMICS INC. 2018 - 2023
  • UAB Diabetes Research Center  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2018 - 2023
  • UAB Diabetes Research Center - Human Physiology Core  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2018 - 2023
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2017 - 2022
  • ACES - ACE Inhibitors Combined with Exercise for Hypertensive Seniors  awarded by National Institute on Aging/NIH/DHHS 2017 - 2022
  • Private Grant  awarded by INSPIRE MEDICAL SYSTEMS, INC. 2017 - 2022
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2017 - 2020
  • Vascular Effects of Mineralocorticoid Receptor Antagonism in Kidney Disease  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2015 - 2020
  • Coronary Flow Reserve to Assess Cardiovascular Inflammation (CIRT-CFR)  awarded by Brigham and Women's Hospital 2016 - 2020
  • Private Grant  awarded by GE HEALTHCARE 2018 - 2019
  • Private Grant  awarded by GE HEALTHCARE 2017 - 2019
  • Private Grant  awarded by Bayer HealthCare 2015 - 2019
  • Symptoms and Skeletal Muscle in Persons with Heart Failure with Preserved Ejection Fraction  awarded by National Institute of Nursing Research/NIH/DHHS 2017 - 2019
  • Race - Adiposity Interactions Regulate Mechanisms Determining Insulin Sensitivity  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2013 - 2019
  • Cardiovascular Inflammation Reduction Trial (CIRT)  awarded by Brigham and Women's Hospital 2013 - 2019
  • University of Alabama at Birmingham Strategically Focused Hypertension Research Center  awarded by American Heart Association 2015 - 2019
  • Influenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure (INVESTED)  awarded by Brigham and Women's Hospital 2017 - 2019
  • Novel Regulators of Fibroblast Growth Factor 23 in Chronic Kidney Disease: Iron Deficiency and Hypoxia  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2017 - 2018
  • Systolic Blood Pressure Intervention Trial (SPRINT) Clinical Center Networks  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2009 - 2018
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2015 - 2017
  • Centers of Research Translation (CoRT)  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2012 - 2017
  • Centers of Research Translation (CoRT) - Project 2  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2012 - 2017
  • Racial Disparities in the Maintenance of Healthy Lifestyles and Their Effect on Cumulative Blood Pressure Burden and Left Ventricular Mass in African Americans and Whites: Data from the CARDIA Study  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2015 - 2017
  • Private Grant  awarded by ASTRAZENECA AB 2013 - 2016
  • Private Grant  awarded by CVRX, INC. 2007 - 2016
  • Mitochondrial Nuclear Interactions and CVD Susceptibility  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2011 - 2016
  • Private Grant  awarded by Bayer HealthCare 2016
  • Private Grant  awarded by Bayer HealthCare 2014 - 2015
  • UAB Diabetes Research and Training Center  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2008 - 2013
  • UAB Diabetes Research and Training Center - Human Biology Core  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2008 - 2013
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2012
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2012
  • SCCOR in Cardiac Dysfunction and Disease  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2005 - 2010
  • Education And Training

  • Doctor of Medicine in History, University of Virginia
  • Full Name

  • David Calhoun
  • Blazerid

  • dcalhoun